DOK6 Antibody

What is DOK6 and what is its functional role in cellular signaling?

DOK6, or Docking protein 6, belongs to the downstream of tyrosine kinase (DOK) family of adaptor proteins. These proteins are enzymatically inert but play crucial roles as scaffolding proteins by providing docking platforms for the assembly of multimolecular signaling complexes . DOK6 specifically promotes Ret-mediated neurite growth and may have significant roles in brain development and/or maintenance .

The protein functions primarily within the RET signaling pathway and possibly the Trk neurotrophin receptor pathway . Its molecular weight is approximately 36-38 kDa, consistent with its predicted size based on amino acid sequence . Within the signaling cascade, DOK6 undergoes post-translational modifications, particularly phosphorylation. On Ret activation, DOK6 becomes phosphorylated on one or more C-terminal tyrosine residues by Src family kinases, which is an important regulatory mechanism for its function .

What is the tissue expression profile of DOK6?

DOK6 demonstrates a tissue-specific expression pattern with predominant expression in neural tissues. It is highly expressed in both fetal and adult brain, with particularly strong expression in the cerebellum . This expression pattern aligns with its proposed functional role in neuronal development and maintenance.

In addition to the brain, DOK6 shows weak expression in several other tissues including the kidney, spinal cord, and testis . This restricted expression pattern suggests specialized functions in neuronal contexts, making it a valuable target for neuroscience research. The high expression in cerebellum particularly points to potential roles in motor coordination, learning, and other cerebellar-dependent functions.

What types of DOK6 antibodies are commercially available?

Several types of DOK6 antibodies are commercially available for research applications:

Most commercially available DOK6 antibodies are rabbit polyclonal antibodies generated against synthetic peptides derived from human DOK6 . These antibodies are typically purified using affinity chromatography with epitope-specific immunogens to ensure specificity .

What applications are DOK6 antibodies suitable for?

DOK6 antibodies have been validated for multiple research applications:

• Western Blotting (WB): All commercially available antibodies are suitable for WB applications, typically at dilutions ranging from 1:500 to 1:2000 . The expected band size is approximately 38 kDa.

• Immunocytochemistry/Immunofluorescence (ICC/IF): DOK6 antibodies can be used for cellular localization studies using immunofluorescence techniques, with recommended dilutions typically between 1:200 and 1:1000 .

• Immunohistochemistry (IHC): Several antibodies are validated for IHC applications with recommended dilutions of 1:100 to 1:300 .

• ELISA: Some antibodies are suitable for ELISA applications, particularly at higher dilutions (e.g., 1:10000) .

These diverse applications make DOK6 antibodies versatile tools for studying the expression, localization, and function of DOK6 in various experimental contexts.

How should I optimize DOK6 antibody dilutions for different applications?

Optimization of antibody dilutions is critical for obtaining specific signals while minimizing background. For DOK6 antibodies, recommended dilution ranges vary by application:

For Western blotting, initial testing should begin within the 1:500-1:2000 range . When using Abcam's ab72730, a 1:500 dilution has been validated for detecting DOK6 in COLO cell extracts . A titration experiment is recommended, testing 3-4 different dilutions to identify the optimal concentration that provides the strongest specific signal with minimal background.

For immunohistochemistry, the recommended range is 1:100-1:300 . The optimal dilution may vary depending on tissue fixation method, section thickness, and detection system. When optimizing, consider:

• Testing both antigen retrieval methods (heat-induced vs. enzymatic)

• Varying primary antibody incubation times (overnight at 4°C vs. 1-2 hours at room temperature)

• Including proper negative controls (omitting primary antibody and using isotype controls)

For immunofluorescence, dilutions between 1:200-1:1000 are recommended . Signal intensity can be influenced by:

• Fixation method (paraformaldehyde vs. methanol)

• Permeabilization conditions

• Blocking reagents

• Secondary antibody selection

For all applications, the optimal dilution should be determined empirically for each specific experimental system, as factors such as expression level, sample type, and detection method can significantly impact results.

What are the recommended positive and negative controls for DOK6 antibody validation?

Proper controls are essential for validating antibody specificity and experimental results:

Positive Controls:

• Cell/tissue types with known DOK6 expression: Brain tissue, particularly cerebellum, serves as an excellent positive control due to high endogenous DOK6 expression . COLO cell extracts have been validated for detecting DOK6 with specific antibodies .

• Recombinant DOK6 protein: Using purified DOK6 protein as a positive control in Western blotting can help confirm antibody specificity and establish the correct molecular weight.

Negative Controls:

• Peptide competition: Pre-incubating the antibody with the immunizing peptide should abolish specific signals. This has been demonstrated with Abcam's ab72730, where the immunizing peptide blocked detection of the 38 kDa band in COLO cell extracts .

• Tissues with minimal DOK6 expression: Tissues with low or undetectable DOK6 expression (based on expression data) can serve as biological negative controls.

• Genetic knockdown/knockout: Samples from DOK6 knockdown or knockout models provide the most stringent specificity controls, demonstrating signal reduction or elimination when the target protein is depleted.

• Secondary antibody-only control: For immunostaining applications, omitting the primary antibody while maintaining all other steps helps identify potential non-specific binding of the secondary antibody.

How can I detect phosphorylated DOK6 in experimental systems?

Detecting phosphorylated DOK6 requires specialized approaches since DOK6 undergoes phosphorylation on C-terminal tyrosine residues upon Ret activation by Src family kinases . While general DOK6 antibodies detect total protein levels, phosphorylation-specific approaches include:

• Phospho-specific antibodies: Although not specifically mentioned in the search results, phospho-specific antibodies targeting known phosphorylation sites on DOK6 would be the most direct approach. If commercially unavailable, researchers might consider custom antibody development against predicted phosphorylation sites.

• Phospho-tyrosine immunoprecipitation: Immunoprecipitating with anti-phosphotyrosine antibodies followed by Western blotting with DOK6-specific antibodies can identify phosphorylated DOK6.

• Phos-tag SDS-PAGE: This technique allows separation of phosphorylated and non-phosphorylated forms of proteins based on mobility shifts, followed by detection with standard DOK6 antibodies.

• Experimental activation of RET signaling: Since DOK6 is phosphorylated upon RET activation , experimental systems can be designed to activate this pathway (e.g., using GDNF ligand for RET) before assessing DOK6 phosphorylation status.

• Phosphatase treatment controls: Treating samples with phosphatases before Western blotting can confirm that mobility shifts or multiple bands are due to phosphorylation.

For validating phosphorylation events, it's crucial to include both positive controls (stimulated samples known to induce DOK6 phosphorylation) and negative controls (phosphatase-treated samples or samples with inhibited upstream kinases).

What methods are recommended for studying DOK6 protein interactions?

Understanding DOK6's role as an adaptor protein requires investigating its protein-protein interactions, particularly within the RET signaling pathway. Recommended approaches include:

• Co-immunoprecipitation (Co-IP): Using DOK6 antibodies to pull down protein complexes, followed by Western blotting for suspected interaction partners. This approach is particularly useful for studying endogenous protein interactions in relevant cell types.

• Proximity ligation assay (PLA): This technique allows visualization of protein interactions in situ with high sensitivity and specificity, using DOK6 antibodies in combination with antibodies against potential interaction partners.

• Yeast two-hybrid or mammalian two-hybrid screening: These systems can identify novel interaction partners of DOK6, though they should be validated using more physiologically relevant methods.

• Mass spectrometry following immunoprecipitation: This unbiased approach can identify novel DOK6-interacting proteins in specific cellular contexts or following stimulation of relevant signaling pathways.

• FRET/BRET assays: These techniques can assess protein-protein interactions in living cells, though they typically require expression of tagged proteins.

When studying DOK6 interactions, it's important to consider the cellular context, as DOK6 primarily functions in neuronal cells and may have cell type-specific interaction partners relevant to its role in neuronal development.

What are common causes of weak or absent signal in DOK6 Western blotting?

When troubleshooting weak or absent signals in Western blotting with DOK6 antibodies, consider these potential issues and solutions:

How can I optimize DOK6 immunostaining in difficult tissue samples?

Optimizing DOK6 immunostaining in challenging tissue samples requires systematic troubleshooting:

• Fixation optimization:

  • Test different fixatives (4% PFA, methanol, acetone) and fixation durations

  • For formalin-fixed samples, evaluate different antigen retrieval methods (citrate buffer pH 6.0 vs. EDTA buffer pH 9.0)

  • Consider dual fixation protocols for better preservation of both morphology and antigenicity

• Signal amplification strategies:

  • Implement tyramide signal amplification (TSA) for low-abundance targets

  • Use biotin-streptavidin amplification systems

  • Consider polymer-based detection systems with multiple secondary antibodies per primary antibody

• Background reduction:

  • Extend blocking steps (2+ hours or overnight) with 5-10% normal serum

  • Add 0.1-0.3% Triton X-100 to blocking and antibody diluents to reduce non-specific membrane binding

  • Include protein blockers like BSA (2-5%) in diluent buffers

  • Pre-absorb primary antibodies with tissue homogenates from negative control samples

• Antibody incubation optimization:

  • Test both short (2-3 hours at room temperature) and long (overnight at 4°C) incubation protocols

  • Increase antibody concentration for challenging samples (starting at 1:100 dilution)

  • Use specialized antibody diluents designed to enhance penetration and reduce background

• Control experiments:

  • Perform peptide competition assays to validate specificity

  • Include no-primary antibody controls to assess secondary antibody background

  • Compare staining patterns with published DOK6 expression data (high in cerebellum, low in non-neural tissues)

What are common pitfalls in data interpretation when using DOK6 antibodies?

Researchers should be aware of several common pitfalls when interpreting results from DOK6 antibody experiments:

• Misinterpreting non-specific bands in Western blots:

  • The expected molecular weight of DOK6 is approximately 38 kDa

  • Validate specificity through peptide competition assays

  • Be cautious of cross-reactivity with other DOK family members that share sequence homology

  • Consider potential splice variants or post-translational modifications that may alter apparent molecular weight

• Over-interpretation of immunostaining patterns:

  • Confirm DOK6 staining patterns with multiple antibodies targeting different epitopes

  • Use appropriate controls including no primary antibody, isotype controls, and peptide competition

  • Compare staining patterns with known DOK6 expression profiles (high in cerebellum)

  • Be cautious when interpreting subcellular localization without confirmatory techniques

• Neglecting species-specific differences:

  • Most antibodies react with human and mouse DOK6 , but verification is needed for other species

  • Consider sequence homology when using antibodies across species; some show predicted reactivity with additional species like pig, zebrafish, and others

  • When studying novel species, validate reactivity using positive control samples

• Ignoring technical limitations:

  • Recognize that antibody performance can vary across applications (WB, IHC, IF)

  • Consider that fixation and sample preparation methods can affect epitope accessibility

  • Be aware that high antibody concentrations may increase non-specific binding

  • Acknowledge batch-to-batch variations in antibody performance, particularly with polyclonal antibodies

• Misattribution of DOK6 function:

  • Confirm functional studies with multiple approaches (not just antibody-based techniques)

  • Remember that DOK6 is part of a larger family; phenotypes may reflect combined functions

  • Consider that DOK6 has tissue-specific roles, particularly in neural contexts

How can DOK6 antibodies be used to study neuronal development?

DOK6 antibodies provide valuable tools for investigating neuronal development given DOK6's role in promoting Ret-mediated neurite growth and potential functions in brain development and maintenance :

• Developmental expression profiling:

  • Track DOK6 expression patterns throughout embryonic and postnatal neural development using immunohistochemistry and Western blotting

  • Compare expression patterns between different brain regions, particularly focusing on the cerebellum where DOK6 is highly expressed

  • Correlate DOK6 expression with developmental milestones and critical periods

• Neurite outgrowth assays:

  • Use immunofluorescence with DOK6 antibodies to visualize DOK6 localization during neurite extension

  • Combine with cytoskeletal markers to understand DOK6's relationship to growth cone dynamics

  • Implement time-lapse imaging with fluorescently tagged DOK6 to monitor real-time changes during neurite growth

• Signaling pathway analysis:

  • Investigate DOK6's role in RET signaling by examining colocalization with RET receptors in developing neurons

  • Study phosphorylation dynamics of DOK6 following neurotrophin treatment

  • Explore interactions between DOK6 and downstream effectors in the context of neuronal differentiation

• Loss/gain-of-function studies:

  • Use DOK6 antibodies to validate knockdown or overexpression efficiency in functional studies

  • Assess morphological and molecular consequences of DOK6 manipulation using immunostaining approaches

  • Combine with electrophysiological recordings to correlate DOK6 expression with functional neuronal maturation

• Synaptogenesis research:

  • Examine DOK6 localization during synapse formation using super-resolution microscopy with DOK6 antibodies

  • Investigate potential synaptic functions of DOK6 by combining with markers for pre- and post-synaptic structures

  • Study activity-dependent regulation of DOK6 expression or localization at synapses

What role might DOK6 play in neurodegenerative disorders?

While the search results don't explicitly mention DOK6 in the context of neurodegenerative disorders, its high expression in brain tissue and role in neuronal development suggest potential relevance :

• Expression studies in disease models:

  • DOK6 antibodies can be used to assess expression changes in animal models of neurodegenerative conditions

  • Compare DOK6 levels in post-mortem tissue from patients with various neurodegenerative disorders versus age-matched controls

  • Investigate cell type-specific changes in DOK6 expression during disease progression

• Potential neuroprotective functions:

  • As an adaptor protein in neurotrophin signaling pathways, DOK6 may influence neuronal survival mechanisms

  • DOK6 antibodies could help characterize its interactions with survival-promoting signaling complexes

  • Manipulation of DOK6 levels followed by assessment of neuronal vulnerability to toxic insults could reveal protective roles

• Synaptic pathology:

  • Many neurodegenerative disorders feature early synaptic dysfunction before neuronal loss

  • DOK6 antibodies can be used to study its potential involvement in synaptic maintenance or plasticity

  • Colocalization studies with synaptic markers in disease models may reveal pathology-associated changes

• Potential biomarker applications:

  • Changes in DOK6 levels or phosphorylation states could potentially serve as disease biomarkers

  • DOK6 antibodies might be valuable for developing immunoassays to detect such changes in accessible biospecimens

• Therapeutic target potential:

  • Understanding DOK6's role in neuronal health might reveal new therapeutic approaches

  • DOK6 antibodies would be essential tools for validating target engagement in drug development efforts

What methodological approaches are recommended for studying DOK6 in complex neural tissues?

Studying DOK6 in complex neural tissues presents unique challenges that require specialized methodological approaches:

• Cell type-specific analysis:

  • Combine DOK6 immunostaining with neuronal, glial, and progenitor cell markers to identify cell-specific expression patterns

  • Implement fluorescence-activated cell sorting (FACS) with DOK6 antibodies to isolate specific neural populations

  • Use single-cell analysis techniques to correlate DOK6 expression with cell identities and states

• Advanced imaging approaches:

  • Apply tissue clearing techniques (CLARITY, iDISCO) to enable whole-brain imaging of DOK6 expression

  • Implement super-resolution microscopy to resolve subcellular localization of DOK6 in neuronal compartments

  • Use expansion microscopy to physically enlarge samples for improved resolution of DOK6 distribution

• In vivo analysis:

  • Develop DOK6 reporter mouse lines to track expression in living tissues

  • Combine with two-photon microscopy for deep tissue imaging

  • Implement cranial window techniques for longitudinal imaging of DOK6 dynamics

• Activity-dependent regulation:

  • Examine DOK6 expression or localization changes following neuronal stimulation protocols

  • Combine DOK6 immunostaining with activity markers (c-Fos, Arc) to correlate with functional neural circuits

  • Use optogenetic or chemogenetic approaches to manipulate specific circuits and assess DOK6 responses

• Proteomic approaches:

  • Implement proximity labeling techniques (BioID, APEX) to identify DOK6 interactors in specific cellular compartments

  • Use spatially resolved proteomics to map DOK6 protein complexes in different brain regions

  • Apply phosphoproteomics to characterize activity-dependent modifications of DOK6 in neural contexts

These methodological approaches, combined with appropriate DOK6 antibodies, can provide comprehensive insights into the functions of this adaptor protein in complex neural tissues.